Kornimate/medical-research-clean huggingface dataset:
development of cardio-vascular emergency patients database using voice and image technology

Conditions: Cardiovascular Diseases

Summary: video and audio data of cardio-vascular patients who visit the emergency department (ed) will be collected to build a database. clinical information retrieved from the database using voice and image technology will be compared to that retrieved by physicians. the degree of agreement will be evaluated.

study objectives: 1. to develop a platform to record video and audio data of cardio-vascular patients who visited the ed. 2. to retrieve clinical information using voice and image technology. 3. to develop a tool to retrieve clinical information using voice and image technology. 4. to build a clinical database using video and audio data using voice and image technology. study design: single-center observational study (tertiary hospital emergency department in korea). a platform to record video and audio data of physicians examining patients will be developed. the camera and microphone will be installed at an optimal location to retrieve video and audio data of cardio-vascular patients. voice and image technology will be used to retrieve clinical information including chief complaint, type and onset of symptoms, past medical history, and physical examination results to build a database. clinical information including examination notes, diagnosis, patient vital signs, test results, and ed results will be retrieved from the hospital database.

Eligibility criteria:
inclusion criteria: * age 19 years or older * visited the emergency department of the study hospital * chief complaint of chest pain, dyspnea, syncope, altered mentality, side weakness, dizziness, and dysarthria exclusion criteria: * patients who do not agree to enroll to this study * pregnant patient * without a family * foreign patients

Keywords: image recognition voice recognition emergency department
prospective study of deep anterior lamellar keratoplasty using acellular porcine cornea

Conditions: Corneal Transplantation

Summary: the performance of keratoplasty is hampered by the limited availability of donor cornea in many countries, especially in asia. for this reason, attempts have been made to fabricate artificial substitutes for natural human cornea. so far, all polymeric biomaterials, such as collagen configurations and plastic compression, could mimic the functional optically transparent but failed to replicate the complicate three-dimension microstructure of natural cornea. therefore, despite some favorable results yielded by polymeric biomaterials, they cannot be suited for long-term use. to overcome these disadvantages, in recent years, porcine cornea appeared specifically attractive for xenotransplantation, because of its accessibility and similarities to natural human cornea. however, xenotransplantation using fresh porcine cornea can occurs hyperacute immune rejection, resulting in graft failure. such transplant rejection can be substantially lessened by using acellular porcine cornea (apc), which preserves the constructure of natural cornea, whilst having well biocompatibility and low antigenicity. these properties feature apc particularly suitable for high-risk keratoplasty, such as corneal grafting in infectious keratitis. use of apc in lk has been shown promise in many preclinical animal studies and initially in human clinic trail. however, to optimize apc biological and biomechanical properties, the strategies for its preparation has evolved extensively over recent years, like various decellularization approaches (e.g. detergents, enzymes, human sera, hypertonic solutions and et al) and additional procedures (e.g. collagen re-crosslinking and repeated frozen-dry). therefore, in the current study, the investigators analyzed the early surgical outcomes of deep anterior lamellar keratoplasty (dalk) using the apc that was very recently approved by the national institutes for food and drug control (nifdc) of china for clinic practice, for management of infective keratitis, including fungal, viral and acanthamoeba keratitis. here major concern of this study was to clarify the behavior of apc after implantation in participants.


Eligibility criteria:
inclusion criteria: corneal diseases not involving the endothelial layer exclusion criteria: * corneal diseases involving the endothelial layer * allergic to pig tissue * do not accept xenotransplantation

Keywords: corneal transplantation xenotransplantation bioegineered cornea
study to evaluate the efficacy and safety of aripiprazole administered with lithium or valproate over 12 weeks in the treatment of mania in bipolar i disorder

Conditions: Bipolar Disorder Mania

Summary: the purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with bipolar i disorder when combined with lithium or valproate over 12 weeks.


Eligibility criteria:
key inclusion criteria: * clinical diagnosis of bipolar i disorder mania, manic or mixed episode, with or without psychotic features * current ongoing lithium or valproate treatment with the possibility of benefiting, based on the investigator's clinical judgment, from adjunctive treatment with aripiprazole * therapeutic serum levels of lithium or valproate and a young mania rating total score of 16 or higher at screening and baseline * participants taking current lithium or valproate treatment combined with antipsychotic medication other than aripiprazole are acceptable, provided that the other antipsychotic medication is washed out at least 3 days prior to the blood draw for therapeutic plasma levels of lithium and valproate determination. long-acting antipsychotics must be washed out prior to entering the double-blind treatment. key exclusion criteria: * women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of investigational product * a diagnosis of delirium, dementia, amnesia or other cognitive disorder, or a psychotic disorder * current diagnosis of delirium, dementia, a cognitive disorder (ie, amnesia), or a psychotic disorder (ie, schizophrenia or schizoaffective disorder) * current diagnosis of bipolar ii disorder, bipolar disorder not otherwise specified, or any other primary psychiatric disorder other than bipolar i disorder mania * thyroid pathology * demonstrated cocaine abuse or dependence within the past 3 months prior to screening. * history of neuroleptic malignant syndrome from antipsychotic agents * manic symptoms that investigator considers refractory to treatment * previous nonresponsive (by investigator judgment) to aripiprazole for manic symptoms * significant risk of suicide based on history, mental status exam, or investigator judgment.
procalcitonin-guided antimicrobial discontinuation

Conditions: Sepsis

Summary: the current study aims to validate the diagnostic use of pct assessing its capability to individualize and shorten the duration of antibiotic therapy in critically ill patients with suspected or confirmed sepsis. in particular, no well-designed intervention study has properly examined the following hypothesis: a pct-guided antibiotic discontinuation strategy enables to reduce antibiotic treatment duration in critically ill patients with suspected or documented sepsis, without harming patient safety.

primary objective: to assess the effect of repeated pct measurements in critically ill patients with clinically suspected or microbiologically documented sepsis on duration of antimicrobial use and to compare this strategy to standard clinical practice, by using an improved pct assay with a sensitivity of 0.06 ng/ml. secondary objectives: to determine the impact of repeated pct measurements on patient outcome (morbidity, mortality, emergence of antibiotic resistance and nosocomial super-infections). main measures: primary: 1. exposure to systemic antimicrobial treatment (in duration of antibiotic treatment and total antibiotic exposure) secondary: 2. cure and failure rate of infection (in n recurrent infections per 100 patients) 3. 28-day case-fatality rate (in n deaths per 100 patients) 4. length of hospital stay (in days) 5. costs of antimicrobial therapy (in chf) 6. rate of nosocomial super-infection (in n super-infections per 100 patients) 7. isolation of multi-resistant microorganisms (in clinical isolates per 100 patient-days)

Eligibility criteria:
inclusion criteria: 1. patients with clinically suspected or microbiologically confirmed bacterial sepsis 2. informed consent exclusion criteria: 1. patients with microbiologically documented infections caused by the following microorganisms: listeria spp, legionella pneumophilia, mycobacterium tuberculosis, staphylococcus aureus 2. patients with fungal infections 3. patients with severe infections due to viruses or parasites (e.g. hemorrhagic fever, malaria) 4. patients with suspected or confirmed bacterial meningitis or endocarditis 5. patients with localized, deep-seated abscesses (e.g. brain abscess) without systemic sepsis 6. patients with chronic, localized infections (e.g. chronic osteomyelitis) without systemic sepsis 7. neutropenic and other severely immuno-compromised patients (patients infected with human immunodeficiency virus and a cd4 count \< 200; patients on immuno-suppressive therapy after solid organ transplantation; patients with cystic fibrosis) 8. withholding of life-support 9. early discharge or death (\< 24 hours after admission) 10. complete absence of antimicrobial treatment despite suspicion of sepsis

Keywords: biological markers procalcitonin critical care diagnosis, differential prospective study sepsis antibiotic stewardship antimicrobial resistance
smell changes & efficacy of nasal theophylline

Conditions: Olfactory Disorder; Anosmia; Viral Infection; Theophylline Causing Adverse Effects in Therapeutic Use; Smell Disorder

Summary: this study evaluates the efficacy and safety of nasal theophylline irrigation in treating smell loss related to a viral respiratory infection. half the participants will undergo nasal theophylline irrigation treatment while the other half will undergo placebo nasal irrigation with saline alone. all participants will have their sense of smell tested before and after 6 weeks of treatment. all participants will also be regularly asked about any potential side effects related to treatment. in addition, the first 10 participants will have their blood drawn to measure their theophylline level after 1 week of starting treatment to ensure it is not abnormally elevated.


Eligibility criteria:
inclusion criteria: * subjective or clinically diagnosed olfactory dysfunction of 6 months to 36 months duration after a presumed viral upper respiratory infection * ability to read, write, and understand english exclusion criteria: * dependence on theophylline for comorbid conditions such as asthma and chronic obstructive pulmonary disease * history of an allergic reaction to theophylline or other methylxanthines * prior sinonasal or anterior skull base surgery * nasal polyposis * history of neurodegenerative disease (ie. alzheimer's dementia, parkinson's disease, lewy body dementia, frontotemporal dementia) * pregnant or breastfeeding mothers * current use of medications with significant (≥40%) interactions with theophylline, which include cimetidine, ciprofloxacin, disulfiram, enoxacin, fluvoxamine, interferon-alpha, lithium, mexiletine, phenytoin, propafenone, propranolol, tacrine, thiabendazole, ticlopidine, and troleandomycin

Keywords: olfactory dysfunction anosmia hyposmia post-viral theophylline adverse effects smell
comparison of volumes of local anesthetics on the efficiency and safety of stellate ganglion block for crps of the arm

Conditions: Complex Regional Pain Syndromes

Summary: the purpose of this study is to compare the efficiency and safety of 2ml versus 5ml of local anesthetics used in stellate ganglion blocks for the treatment of complex regional pain syndrome of the arm.

to evaluate if 2ml of 0.2% ropivacaine is less effective in decreasing pain scores by more than 50% when compared to 5ml of 0.2% ropivacaine. to evaluate if 2ml of 0.2% ropivacaine is causes less side effects when compared to 5ml after a stellate ganglion block.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of complex regional pain syndrome of the arm according to the budapest criteria and having already received a minimum of 3 stellate ganglion blocks. only patients having received a minimum of 3 stellate ganglion blocks will be included since it is expected to have a progressive and sustained decrease in pain scores during the first 3 blocks. * asa 1 to 3 included exclusion criteria: * patient refusal * contra-indications to the stellate ganglion block procedure such as coagulopathy, anticoagulants or anti platelet therapy other than aspirin, systemic or injection site infection, important neck deformity (post-radiotherapy or surgery, etc.), severe chronic obstructive pulmonary disease, contralateral diaphragm paralysis or contralateral pneumonectomy * allergy to local anesthetics * concomitant pain syndrome other than complex regional pain syndrome of the arm * liver or kidney failure (crcl \< 30 ml/min) * inability to understand à verbal numeric pain score scale after careful explanations * inability to consent

Keywords: stellate ganglion local anesthetic
tailored messages to increase eye examination behavior

Conditions: Eye Disease; Eye Care

Summary: the purpose of this project is to test two different types of health messages, one that is developed for a specific group (targeted) and the other that is more personalized to individuals (tailored), to see which is better at changing how often people have their eyes examined. we hypothesize that people who get the tailored messages will be more likely to get a dilated eye exam than people who receive the targeted messages.

studies have shown that people are not getting their eyes examined on a regular basis, even though dilated eye exams can detect eye diseases like glaucoma and diabetic retinopathy early, before significant vision loss has developed. early detection can lead to earlier treatment, which can save sight by preventing or slowing the progression of these eye diseases. in this project we designed, implemented, and are now evaluating tailored and targeted print health messages to increase eye examination behavior in an african-american population 65 years of age and older, a group at increased risk of glaucoma and diabetes.

Eligibility criteria:
inclusion criteria: * african-american * 65 years of age or older * no dilated fundus exam in past 2 years exclusion criteria: * appointment for dilated fundus exam scheduled * no access to phone

Keywords: tailored health messages glaucoma diabetic retinopathy dilated fundus exams health behavior
multimodal mri-guided rtms to treat refractory hallucinations

Conditions: Hallucinations; Schizophrenia; Perceptual Disorders

Summary: * the efficacy of neuro-navigated rtms for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (rct) * this study will use a combination of different mri modalities (fmri and dti) to define with precision rtms brain-targets in the case of multisensory hallucinations * the investigators anticipate that multimodal mri-guided rtms will allow a significant improvement in the efficacy of neuromodulation treatment of refractory hallucinations


Eligibility criteria:
inclusion criteria: * right-handed female/male, \[13-60 y.o.\], * schizophrenia (dsm-iv-tr diagnosis), * drug-resistant hallucinations (kinon \& kane criteria, 1993), * unmodified antipsychotic dosage during the 30 days preceding rmts, * no anticonvulsive medication, * no neurological disorder, no addictive behavior, * matched for sex, age and panss scores, * consent to participate to the study, exclusion criteria: * pregnancy * contraindication to mri scan * contraindication to rtms treatment * claustrophobia * no social insurance

Keywords: repetitive transcranial magnetic stimulation neuronavigation functional magnetic resonance imaging diffusion tensor imaging
impact of covid-19 pandemic on management of head and neck cancers

Conditions: Head and Neck Cancer; Covid19; Patient Care

Summary: since its emergence in late december 2019, the sars-cov-2 coronavirus has spread rapidly, causing a global health crisis. the disease caused by this highly contagious respiratory virus is called covid-19. at the beginning of august 2020, there were more than 194,000 confirmed cases in france - including approximately 16,000 cases in the hauts-de-france area - and more than 30,300 deaths. cancer patients are generally susceptible to respiratory infections, and cov-2-sars is no exception. early chinese studies reported a higher rate of cov-2-sars infection in people with cancer (or a history of cancer) than in the general population, with more severe forms and with an increased risk if surgery or chemotherapy is performed in the month prior to infection. the purpose of this study is to describe the management modalities of patients with h\&n (head and neck) cancer during the covid-19 pandemic in the maxillofacial surgery department of chu amiens-picardie.


Eligibility criteria:
inclusion criteria: * patient diagnosed with cancer of the upper aero digestive tract * patient benefiting from a medical consultation * patient benefiting from a multidisciplinary consultation meeting for treatment decision between 01/03/2020 and 28/02/2021. exclusion criteria: * patient diagnosed with cancer other than upper aero digestive tract cancer * patient whose treatment decision was made before 01/03/2020 (date considered as the beginning of the epidemic at the chu amiens-picardie).

Keywords: head and neck cancer upper aero digestive tract cancer covid19 patient care
a 16-week study to evaluate the effect of advair diskus™ 250/50mcg on arterial stiffness in subjects with chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the purpose of this study is to evaluate in patients with chronic obstructive pulmonary disease (copd) if advair diskus™ 250/50mcg bid modifies arterial stiffness which is a measure associated with risk of heart disease.

this is a multicenter, randomized, double-blind, placebo controlled study to evaluate the effect of fluticasone propionate/salmeterol diskus 250/50mcg (fsc) bid on arterial stiffness in copd subjects. following a 1 to 14 day run-in period, approximately 250 subjects will be randomly assigned to double-blind treatment for 12 weeks. after the 12 week treatment period, subjects in both treatment arms will receive open label tiotropium bromide handihaler18mcg (tio)qd for 4 weeks in addition to their continued study drug (either fsc250/50 or placebo). the primary measure of efficacy is pulse wave velocity (pwv) at endpoint. secondary efficacy measures include augmentation index (aix), biomarkers of cardiovascular disease, measures of lung function. (e.g. fev1). safety will be assessed through the collection of adverse events and copd exacerbations. exploratory endpoints include the effect of tiotropium on pwv and aix when added to placebo or fsc. treatment groups will be stratified based on current smoking status. there will be a total of 6 study visits (screening, randomization, and after 4, 8, 12 and 16 weeks of treatment). a follow-up phone contact for collection of adverse event and pregnancy information (if applicable) will be conducted approximately 14 days following the last study visit.

Eligibility criteria:
inclusion criteria: * signed and dated written informed consent obtained from the subject and/or subject's legally acceptable representative prior to study participation. * males or females greater then or equal to 50 years of age. * a post-albuterol fev1/fvc ratio of \< or equal to 0.70 * a post-albuterol fev1 \< 80% of predicted normal. * patients can be current or fomer smoker and must have a cigarette smoking history of \> greater then or equal to 10 pack-years . exclusion criteria: * a current diagnosis of asthma * a body mass index (bmi) of \> or equal to 35kg/m2 * a respiratory diagnosis other than copd (e.g., lung cancer, bronchiectasis, sarcoidosis, tuberculosis, lung fibrosis).

Keywords: chronic obstructive pulmonary disease arterial stiffness computed tomography pulse wave velocity pulse wave analysis
comparative effectiveness of biologics or small molecule therapies in inflammatory bowel disease (ibd)

Conditions: Crohn's Disease; Ulcerative Colitis

Summary: the purpose of this study is to assess effectiveness of vedolizumab versus ustekinumab in patients with crohn's disease and vedolizumab versus tofacitinib in patients with ulcerative colitis, after non-response to anti-tumor necrosis factor (tnf) medications, using data from two existing cohorts.

this study is a secondary analysis using data from participants in the ibd partners and sparc-ibd cohorts. data received from ibd partners consists of patient-reported outcomes gathered via online surveys (baseline and 6-month follow-ups). data received from sparc-ibd consists of patient-reported outcomes gathered via surveys (baseline and follow-ups) as well as data from clinical records.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18; * diagnosis of cd or uc (as reported by participant for ibd partners registry and/or physician for sparc-ibd cohort); * initiated vedolizumab or ustekinumab for cd, or initiated vedolizumab or tofacitinib for uc; treated with anti-tnf prior to vedolizumab/ustekinumab/tofacitinib. exclusion criteria: * less than 18 years of age
using dna-typing and erythrocyte microparticle analysis to detect blood doping

Conditions: Blood Disease; Blood Transfusion, Autologous; Blood Doping; Blood Transfusion, Homologous

Summary: a total of 12 subjects will be recruited for participation in this study. 6 subjects will receive re-infusion of autologous blood, and 6 subjects (anemic patients) will receive a homologous transfusion.

homologous blood transfusions (hbt) and autologous blood transfusions (abt) are abused by athletes to illegally increase their hemoglobin mass and subsequently improve oxygen transport. anti-doping labs use flow-cytometry to detect hbt in cheating athletes, but athletes avoid being tested positive by matching their blood for minor blood groups before transfusion. recent publications suggest that dna typing by capillary electrophoresis or rt-pcr might be an alternative way to detect this kind of doping in athletes. unfortunately, no data exist on the clearance of dna after transfusion of one bag of blood using this methodology. for the detection of doping with abt, there is no direct method available and only the biological passport, a longitudinal collection of hematological parameters can indicate doping. recently rbc microparticles (rbc-mps) have been described as a potential biomarker for autologous transfusion. however, also for this methodology, no data on the clearance time of rbc-mps are available. thus, in this world anti-doping agency (wada) approved and sponsored project. the investigators plan to perform a clinical trial in which six healthy subjects receive an abt and six healthy subjects or patients a hbt. blood samples will be collected before and at several time-points after transfusion. for the detection of hbt the samples will be analyzed by the official method (cytometry), and the two genotyping methods (str and rt-pcr) to compare these different techniques and to see if dna-typing can replace cytometry. for the abt the collected samples will be analyzed for rbc-mps on a cytometer dedicated for microparticles.

Eligibility criteria:
inclusion criteria: * both genders, * age 20-50 years and * preferably physically active but no elite athletes subjected to anti-doping testing. exclusion criteria: * vulnerable subjects * not willing to participate * not signing the icf * patients with end-organ failure